Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2022 13:25 ET | Source: Nkarta, Inc.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
April 08, 2022 07:58 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
March 29, 2022 08:02 ET | Source: Nkarta, Inc.

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors

Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc....
March 17, 2022 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory...
March 08, 2022 16:35 ET | Source: Nkarta, Inc.

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
February 10, 2022 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
December 16, 2021 08:02 ET | Source: Nkarta, Inc.

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
December 13, 2021 16:02 ET | Source: Nkarta, Inc.

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
November 12, 2021 07:15 ET | Source: Nkarta, Inc.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
November 10, 2021 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDSSuccessful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in...